Last Updated : May 9, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type Sort ascending | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Replagal | Agalsidase alfa | Fabry Disease | Do not list | Complete | ||
Fabrazyme | Agalsidase beta | Fabry Disease | Do not list | Complete | ||
Viread | Tenofovir disoproxil fumarate | HIV infection | Do not list | Complete | ||
Adderall XR | Mixed amphetamine salts | Attention deficit hyperactivity disorder | Do not list | Complete | ||
Zavesca | Miglustat | Gaucher disease | Do not list | Complete | ||
Ciprodex | Ciprofloxacin hydrochloride and dexamethasone otic suspension | Otitis media with otorrhea & otitis externa, acute | Do not list | Complete | ||
Forteo | Teriparatide (rDNA origin) injection | Osteoporosis | Do not list | Complete | ||
Gynazole.1 | Butoconazole nitrate | Vaginal infection | Do not list | Complete | ||
Sensipar | Cinacalcet hydrochloride | Secondary hyper-parathyroidism in chronic kidney disease | Do not list | Complete | ||
Relpax | Eletriptan hydrobromide | Migraine | Do not list | Complete |